Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms. 2015

Efsevia Vakiani, and Rona Yaeger, and Sylvester Brooke, and Yi Zhou, and David S Klimstra, and Jinru Shia
Departments of *Pathology †Medicine ‡Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY.

Reliable assessment of the BRAF mutation status is becoming increasingly important in the clinical management of colorectal carcinomas (CRC). The aim of this study was to investigate the use of a recently developed mutation-specific antibody (VE1; SpringBio, Pleasanton, CA) to detect the BRAF V600E protein in paraffin tissue. We analyzed by immunohistochemistry (IHC) 117 cases that had been evaluated for BRAF mutation using a MALDI-TOF mass spectrometry-based assay. Immunohistochemical staining was evaluated without the knowledge of the genetic data and was considered positive when there was distinct homogenous cytoplasmic staining in the tumor cells. The analyzed cases included 4 polyps, 63 primary CRC, and 50 metastatic CRC. Forty-five of the 46 (97.8%) cases that were positive by IHC had a BRAF V600E mutation by genetic analysis; the 1 discordant case was notably of signet ring cell type. Similarly, 66 of the 67 (98.5%) cases that were negative by IHC were also negative by genetic analysis. Four cases that showed weak cytoplasmic staining and/or nuclear staining in the tumor cells were considered to be IHC equivocal; by genetic analysis, 2 of the 4 were positive and 2 were negative. The overall sensitivity and specificity of IHC for the detection of a BRAF V600E mutant tumor was 93.7% and 95.6%, respectively. Our results support the use of VE1 IHC for identification of colorectal neoplasms harboring the BRAF V600E mutation. Difficulties in immunohistochemical interpretation may arise in a small number of cases and in those cases molecular testing is required.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D003111 Colonic Polyps Discrete tissue masses that protrude into the lumen of the COLON. These POLYPS are connected to the wall of the colon either by a stalk, pedunculus, or by a broad base. Colonic Polyp,Polyp, Colonic,Polyps, Colonic
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000912 Antibodies, Neoplasm Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS. Neoplasm Antibodies,Tumor Antibodies,Antibodies, Tumor
D000915 Antibody Affinity A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes. Affinity, Antibody,Antibody Avidity,Avidity, Antibody,Affinities, Antibody,Antibody Affinities,Antibody Avidities,Avidities, Antibody
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity

Related Publications

Efsevia Vakiani, and Rona Yaeger, and Sylvester Brooke, and Yi Zhou, and David S Klimstra, and Jinru Shia
July 2016, Histopathology,
Efsevia Vakiani, and Rona Yaeger, and Sylvester Brooke, and Yi Zhou, and David S Klimstra, and Jinru Shia
June 2012, The American journal of surgical pathology,
Efsevia Vakiani, and Rona Yaeger, and Sylvester Brooke, and Yi Zhou, and David S Klimstra, and Jinru Shia
September 2020, Bulletin du cancer,
Efsevia Vakiani, and Rona Yaeger, and Sylvester Brooke, and Yi Zhou, and David S Klimstra, and Jinru Shia
March 2014, Human pathology,
Efsevia Vakiani, and Rona Yaeger, and Sylvester Brooke, and Yi Zhou, and David S Klimstra, and Jinru Shia
January 2019, Iranian journal of pathology,
Efsevia Vakiani, and Rona Yaeger, and Sylvester Brooke, and Yi Zhou, and David S Klimstra, and Jinru Shia
November 2023, Journal of cancer research and clinical oncology,
Efsevia Vakiani, and Rona Yaeger, and Sylvester Brooke, and Yi Zhou, and David S Klimstra, and Jinru Shia
January 2017, Clinical cancer research : an official journal of the American Association for Cancer Research,
Efsevia Vakiani, and Rona Yaeger, and Sylvester Brooke, and Yi Zhou, and David S Klimstra, and Jinru Shia
January 2018, Case reports in surgery,
Efsevia Vakiani, and Rona Yaeger, and Sylvester Brooke, and Yi Zhou, and David S Klimstra, and Jinru Shia
August 2013, Genes, chromosomes & cancer,
Efsevia Vakiani, and Rona Yaeger, and Sylvester Brooke, and Yi Zhou, and David S Klimstra, and Jinru Shia
March 2013, Applied immunohistochemistry & molecular morphology : AIMM,
Copied contents to your clipboard!